Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy
Executive Summary
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
You may also be interested in...
Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule
Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.
US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising
Firm to promote Nasonex 24HR Allergy nasal spray with cartoon bee familiar with brand’s marketing as an Rx product. It doesn't anticipate receiving OTC market exclusivity along with approval of first OTC mometasone furoate product in US.